Clinical Trials Logo

Clinical Trial Summary

Setup of comparative trial The goal of this study is to determine whether one surgical treatment for chronic subdural hematoma is better than the other. Patients with a clear indication for drainage of subdural hematoma (as stated under "Surgical options") will be randomized into three groups. One group will receive twist drill craniostomy followed by drainage during 48 hours. One group will undergo burr hole drainage (single if possible, double if necessary) with irrigation and drainage during 48 hours postoperatively. One group will undergo a minicraniotomy with trephine or craniotome, with wide opening of all visible membranes, rigorous irrigation and placement of Jackson-Pratt drain, followed by closed system draining during 48 hours. Postoperative results and complications will be compared between the three groups.


Clinical Trial Description

Study design The study is set up as an open randomized controlled three-arm trial. Patients will be randomized into three groups.

Study setup and procedures The goal of this study is to determine if one surgical treatment for chronic subdural hematoma is better than the other. Patients with a clear indication for drainage of subdural hematoma (as stated under "Surgical options") will be randomized into three groups. One group will receive twist drill craniostomy followed by drainage during 48 to 96 hours. One group will undergo burr hole drainage (single if possible, double if necessary) with irrigation and drainage during 48 to 96 hours postoperatively. One group will undergo a minicraniotomy with trephine or craniotome, with wide opening of all visible membranes, rigorous irrigation and placement of Jackson-Pratt drain, followed by drainage during 48 to 96 hours.

Patients diagnosed with chronic subdural hematoma on CT scan, will be operated on as soon as possible. The type of operation will be determined by randomization. The duration of surgery as well as presence of brain reexpansion (in case of burr hole or minicraniotomy) will be recorded. Postoperatively, patients will be transferred to the neurosurgery ward with a subdural drainage system in place. Drainage system is removed 48 to 96 hours postoperatively, regardless of the type of operation (48 hours standard; longer period of drainage if drainage less than 50cc/24h evaluated on the second 24 hours postoperatively. Maximal time of continuous drainage is 4 days or 96 hours postoperatively). Drained volume will be recorded. Evaluation will be performed preoperatively, 48h postoperatively, on discharge, after 6 weeks and after 6 months, and will include:

- Age, sex, comorbidities (anticoagulation or coagulopathy, dementia, etc)

- Clinical status (cognitive state (orientation in time, place and person), Speech (aphasia/dysarthria), Motor function (hemiplegia/paresis); walking independently (y/n); independence for ADL (y/n); Markwalders Scale, modified Rankin Scale

- Imaging characteristics (location (frontal/parietal/occipital, uni-bilateral), size (max diameter), Density(Hounsfield units, age of hematoma), membranes (y/n). An approximate total of five CTscans will be performed, totaling (5x2=)10mSv of radiation exposure Length of hospital stay will be recorded. The primary endpoint will be the reoperation rate at 40 days. We hypothesize that subdural hematomas treated by minicraniotomy will require less reoperation (reduced to 5%) than burr hole craniostomy or twist drill craniotomy (15 to 25% according to literature).

Secondary endpoints: Clinical endpoints: Duration of operation, technical difficulties during operation. Duration of hospital stay. Improvement of Clinical status and speed thereof, Improvement of CT-imaging characteristics, complication rate (bleeding, local or systemic infection, epilepsy,…). We expect that subdural hematomas operated on by minicraniotomy and large opening of membranes will lead to quicker improvement of CT-imaging than burr hole treatment or twist drill craniotomy.

Exploratory endpoints To determine which type of intervention can be beneficial to which type of patients. Hypothesis is that in case of homogenous chronic subdural hematoma, twist drill craniostomy would pose the least risks, whereas in multiloculated mixed-density hematomas, minicraniotomy would be the best option.

The subjects Number of subjects A total of 150 patients will be included in the study. Inclusion criteria All consecutive patients with chronic subdural hematoma with indication for surgical intervention: clinical symptoms as a result of the subdural collection, or important mass effect (as indicated by a midline shift of more than 5mm) Exclusion criteria Patients under the age of 18 will be excluded Patients who have undergone previous cranial surgery which would limit surgical options (for example bone flap already in place) Replacement of subjects Dropout, in the case of this trial, would only signify loss to follow-up since patients will be operated on after consenting to participation in the trial. In case of dropout, the available data will be evaluated and included in the analysis when possible. If dropout occurs after the scheduled six weeks postoperative visit, data is still usable for analysis of primary endpoint. Data from earlier on in treatment (for example duration of surgery, hospital stay, etc) will be usable for analysis of secondary endpoints.

Restrictions and prohibitions for the subjects Antiaggregant drugs (Aspirin, Asaflow, Cardioaspirine, Plavix, Clopidogrel, Ticlid,…) will be stopped for at least 5 days (ideally 10days) before surgery when possible and, if necessary (this will be discussed with the treating physician/cardiologist), replaced by short acting low molecular weight heparins given subcutaneously (no administration on the day of surgery). Anticoagulants (Sintrom, Marcoumar, Marevan) will be replaced by short acting low molecular weight heparins given subcutaneously (no administration on the day of surgery).

Study analysis Sample size calculation Power and sample size estimations are based on data from the literature indicating that the reoperation rate at 40 days for burr hole craniostomy or twist drill craniotomy ranges from 25% to 15% (control groups), and our assumption that minicraniotomy would decrease the reoperation rate at 40 days to 5%. In a test for trend in proportions, sample sizes of 49, 49, and 49 are obtained from 3 groups with proportions equal to 0.25, 0.15, and 0.05. The total sample of 147 subjects achieves 81% power to detect a linear trend using a two-sided Z test with continuity correction and a significance level alpha of 0.05.

Randomization Randomization will be implemented using Research Randomizer (Urbaniak, G. C., Plous, S. (2011). Research Randomizer (Version 3.0) [Computer software]) Data for randomization was retrieved on September 25th, 2011, from http://www.randomizer.org. Three treatments will be randomized for 50 reps (totaling 150 patients) Analysis of the samples Statistical analysis will be performed by Patrick Haentjens (Uz Brussel, Laarbeeklaan 101 1090 Jette; tel 024777909) Statistical analysis Data will be presented as number of cases including nominator and denominator values (and percentages) for categorical variables and as mean values and standard deviation (SD) for continuous variables. Differences between treatment arms will be presented as absolute between-group differences with corresponding 95% confidence intervals (95% CI). Differences between treatment arms will be assessed by one-way ANOVA for continuous variables and the test for trend in proportions for categorical variables. All tests will be two-sided, and a P-value of less than 0.05 will be considered to indicate statistical significance.

Quality control and quality assurance Continuous ad-hoc analysis of clinical results and of data acquisition and data management will take place in a weekly meeting with all cooperating neurosurgeons; this clinical analysis is independent of statistical analysis. In case of aberrant results from one procedure or another, results will be evaluated and measures will be taken. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02655445
Study type Interventional
Source Universitair Ziekenhuis Brussel
Contact
Status Completed
Phase N/A
Start date January 2012
Completion date March 2020

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06347796 - Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study N/A
Recruiting NCT04065113 - Middle Meningeal Artery Embolization for Chronic Subdural Hematoma N/A
Recruiting NCT02938468 - Mgt of Chronic Subdural Hematoma Using Dexamethasone Phase 2/Phase 3
Completed NCT03307395 - Middle Meningeal Artery Embolization for Treatment of Chronic Subdural Hematoma N/A
Terminated NCT04502745 - A Study to Evaluate Endoscope-assisted, Minimally-invasive Cortical Access System for Chronic Subdural Evacuation N/A
Terminated NCT03353259 - Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery Phase 2/Phase 3
Recruiting NCT02568124 - Tranexamic Acid in Chronic Subdural Hematomas Phase 2/Phase 3
Completed NCT02282228 - Detecting Chronic Subdural Hematoma With Microwave Technology N/A
Recruiting NCT05143216 - High Concentration Oxygen Therapy for Pneumocephalus in Chronic Subdural Haematoma: A Prospective Observational Study
Active, not recruiting NCT04816591 - Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA N/A
Recruiting NCT06401772 - The Effectiveness and Safety of Body Posture in Preventing Postoperative Recurrence for Chronic Subdural Hematoma N/A
Completed NCT06134206 - Burr Hole Ultrasound Study N/A
Recruiting NCT03666949 - General Anesthesia Versus Locoregional Anesthesia for Evacuation of Chronic Subdural Hematoma N/A
Recruiting NCT03280212 - Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma Phase 3
Completed NCT03447327 - Outcome of Single Burr Hole Under Local Anaesthesia in the Management of Chronic Subdural Hematoma N/A
Recruiting NCT05374681 - Efficacy of a Minimally Invasive Therapy Adjuvant to the Standards of Care by Cyanoacrylate Embolization N/A
Recruiting NCT05267184 - Swedish Trial on Embolization of Middle Meningeal Artery Versus Surgical Evacuation in Chronic Subdural Hematoma N/A
Not yet recruiting NCT05900557 - Neurologic Deficits and Recovery in Chronic Subdural Hematoma N/A
Completed NCT02757235 - The Swedish Study of Irrigation Fluid Temperature in the Evacuation of Chronic Subdural Hematoma N/A
Terminated NCT02111785 - Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma Phase 2/Phase 3